Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.

已完结 10 由 36 发布于 2026/7/30 10:16:58

DOI:10.1093/eurheartj/ehag148
作者：Marc S Sabatine 1, Ulrich Laufs
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1093/eurheartj/ehag148

Oxford University Press

Abstract：On the basis of seminal genetic discoveries, proprotein convertase subtilisin/kexin Type 9 (PCSK9) inhibitors were developed as a new class of LDL cholesterol-lowering drug, with a potency o

应助信息

20小时前

同学羊小

a2d792f78bbd11f1bed934735aa3bc31.pdf 已采纳

20小时前

Book学术机器人

2026/7/30 10:16:58 未找到该文献，机器人已退出，请等待人工下载

2026/7/30 10:16:58 Book学术AI机器人收到请求，开始寻找文献

2026/7/30 10:16:58 已向机器人发送请求

20小时前

36 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Cistanche deserticola extract and its active components, echinacoside, ameliorate sarcopenia by activating the IGF-1/PI3K-AKT pathway to modulate ferroptosis.